ECOG-ACRIN Operations Center

描述(由申请人提供)：临床试验继续是推进癌症患者护理和改善结果的努力的基石。ECOG和ACRIN总共拥有65年以上进行高影响力临床试验的经验，这些试验帮助塑造了临床实践。为了响应国家临床试验网络(NCTN)的倡议，ECOG和ACRIN合并了他们互补的科学计划，组成了ECOG-ACRIN癌症研究小组(E-A)。我们提出了一项计划，重点是有效地开发和实施从早期发现到晚期疾病治疗的癌症护理连续过程中改变实践的科学。我们利用我们科学组织内部在成像、癌症生物学和治疗方面的综合专业知识，与达纳·法伯癌症研究所和布朗大学的生物统计和数据管理中心密切合作，提出一系列治疗方案和先进的成像试验，这些试验认识到生物标记物的重要性，以识别适当的患者亚群进行精确的靶向干预。E-A生物信息库、图像数据库和相关的翻译科学中心将利用在试验背景下收集的数据进行相关科学研究，以促进我们对癌症生物学和治疗效果的理解。我们继续与癌症中心和孢子研究项目无缝集成，以创建一个将NCI支持的科学转化为临床试验的界面，并吸引初级研究人员加入NCTN。我们建议继续在NCTN范围内合作，贡献高质量的试验、在先进成像方面的领先地位、联合试验开发和重要的NCTN操作基础设施。E-A将利用独特的临床信息学专业知识来贡献一个带注释的图像和标本、实验室分析和临床数据的数据仓库，以促进科学发现。E-A将贡献一个由37个主要成员机构、200个附属机构、36个CCOP和基于少数群体的CCOP组成的应计网络，这些网络在过去6年中为临床试验积累了33750名患者。E-A的定位是为NCTN做出独特的贡献，努力将NCI支持的科学转化为癌症患者的改善结果。 相关性：ECOG-ACRIN的主要目标是提供必要的支持，以进行相关和严格的临床试验，这些试验通过提高质量而有利于公众健康 以及对癌症患者的护理标准。

DESCRIPTION (provided by applicant): Clinical trials continue to be a cornerstone to the effort to advance care and improve outcomes for cancer patients. ECOG and ACRIN collectively have over 65 years of experience conducting high impact clinical trials that have helped shaped clinical practice. In response to the National Clinical Trials Network (NCTN) initiative, ECOG and ACRIN have merged their complementary scientific programs to form the ECOG-ACRIN Cancer Research Group (E-A). We propose a program focused on the efficient development and implementation of practice-changing science along the cancer care continuum from early detection through treatment of advanced disease. We take advantage of combined expertise in imaging, cancer biology and therapy within our scientific organization, working closely with the biostatistics and data management center at the Dana Farber Cancer Institute and Brown University, to propose a portfolio of treatment and advance imaging trials that recognize the importance of biomarkers to identify appropriate patient subgroups for precisely targeted intervention. The E-A biorepositories, image database and associated translational science centers will leverage the data collected in the context of trials to perform correlative science studies that advance our understanding of cancer biology and treatment effect. We continue to seamlessly integrate with Cancer Center and SPORE research programs to create an interface for translating NCI-supported science into clinical trials and to attract junior investigators intothe NCTN. We propose to continue collaborating across the NCTN, contributing high quality trials, leadership in advance imaging, joint trial development and important NCTN operational infrastructure. E-A will leverage unique clinical informatics expertise to contribute a data warehouse of annotated images and specimens, laboratory analytics and clinical data to foster scientific discovery. E-A will contribute an accrual network of 37 main member institutions, 200 affiliates, 36 CCOPs and minority-based CCOPs that have accrued 33750 patients to clinical trials over the last 6 years. E-A is positioned to make unique contributions to the NCTN, working to translate NCI-supported science into improved outcomes for cancer patients. RELEVANCE: The primary goal of ECOG-ACRIN is to provide the support necessary to conduct relevant and rigorous clinical trials, which benefit public health by improving the quality and standard of care for cancer patients.